NCT02297425View on ClinicalTrials.gov

A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2015

Primary Completion Date

March 31, 2018

Study Completion Date

March 31, 2018

Conditions
Advanced EGFRm (Del 19 or L858R +/- T790M) NSCLC
Interventions
DRUG

PF-06459988

The study will evaluate PF-06459988 PO (tablets) continuous daily dosing in 21 day cycles. The starting dose for PF-06459988 will be 50 mg PO daily. The escalation/de-escalation rules will follow the modified toxicity probability interval method with adjustments using the DLT rate and maximum size per dose level of 10 patients

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02297425 - A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer | Biotech Hunter | Biotech Hunter